Venetoclax in the treatment of chronic lymphocytic leukemia
- 25 April 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 15 (5) , 353-366
Abstract
Introduction: Venetoclax, an antagonist of BCL-2 protein plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL). It has been approved by the FDA for the treatment of relapsed/refractory CLL with del17p, and by the EMA for patients with del17p/TP53 mutation who have failed a BCR inhibitor, or in patients without those aberrations who have failed previous therapy, regardless of their genetic/molecular profile. Venetoclax in combination with rituximab has been also approved for the treatment of CLL after at least 1 prior therapy, regardless of del17p. Areas covered: This article reviews the chemical structure, mechanisms of action, pharmacokinetic and the clinical applications of venetoclax in monotherapy and in combined treatment of CLL. Publications dated 2010 through March 2019 were obtained from the MEDLINE database. The proceedings of the American Society of Hematology held during the last five years were also included. Expert opinion: Venetoclax shows high efficacy, a favorable toxicity profile and a high rate of minimal residual disease negativity, which is thought to have an impact on overall survival. It is efficient in patients with del17p/TP53 mutations, the incidence of which increases during clonal CLL evolution, and after failure of BCR pathway inhibitors.Keywords
Funding Information
- Medical University of Lodz (503/1-093-01/503-11-004)
- Foundation for the Development of Diagnostics and Therapy
This publication has 61 references indexed in Scilit:
- ABT‐199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not plateletsBritish Journal of Haematology, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- BH3-only proteins: Orchestrators of apoptosisBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Apoptotic cell signaling in cancer progression and therapyIntegrative Biology, 2011
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- An overview of chronic lymphocytic leukaemia biologyBest Practice & Research Clinical Haematology, 2010
- Diagnostic issues in chronic lymphocytic leukaemia (CLL)Best Practice & Research Clinical Haematology, 2010
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemiaBlood, 2009
- Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamiliesNature Cell Biology, 2006
- Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeuticsCancer Cell, 2002